Paris-based Phagos Secures €25 Million To Advance Sustainable Antibiotic Alternatives

Founded in 2021 by Alexandros Pantalis and Dr. Adèle James, Phagos develops bacteriophage-based therapies a natural alternative to antibiotics and is the first company authorised to market personalised phage veterinary treatments in the EU.

The funding will accelerate deployment of veterinary treatments, advance Phagos’ patented AI-driven phage discovery platform, and support international expansion across Europe, Asia, and the Americas.

Read Also - Arizona-based Gowan Company Acquires Dutch Agtech Firm Ceradis

Phagos addresses the urgent global challenge of bacterial resistance, a leading cause of human and animal mortality that contributes to food waste, economic losses, and millions of deaths annually. In livestock, one in three antibiotics is now ineffective, tripling since 2000.

By combining microbiology and AI, Phagos designs ultra-precise, personalised phage therapies to target bacterial infections like Salmonella and E. coli, with long-term ambitions in human health. Its regulatory approval makes it the first company worldwide to commercialise personalised phage veterinary drugs, and its patented AI predicts interactions between phages and bacteria, enabling scalable and targeted treatments.

The investment will expand veterinary solutions, enhance R&D, scale AI technology, and support global collaborations. Phagos’ team 90% scientific and technical experts will grow to drive product development, market launches, and worldwide expansion.

“We are convinced that phage therapy can transform the history of medicine just as antibiotics did in the last century. This funding gives us the means to accelerate our mission and make this alternative accessible, fast, and effective against the rise of bacterial resistance. Thanks to our regulatory breakthroughs and our patented platform combining microbiology and artificial intelligence, we now have the opportunity to establish phage therapy as a global reference solution: for animal health today, and for human health tomorrow,” said Alexandros Pantalis and Adèle James, co-founders of Phagos.

“Antimicrobial resistance is a defining challenge for global food systems. With the unprecedented regulatory approval of its discovery platform, Phagos is leading the way in deploying phage therapies as a real, already actionable alternative to antibiotics. Our investment in Phagos underscores our strong commitment to deep tech innovations that drive a healthier, more sustainable, and resilient food supply,” said Anne-Valérie Bach, Managing Director of Capagro.

“Phagos’ pioneering platform provides a high-efficiency alternative to antibiotics, offering a promising solution to a major global health crisis. This investment will help the company become a category-defining leader, reshaping how bacterial infections are treated with a transformative impact on both animal and human health in a massive global market,” added Rob Kniaz, Founder and Emeritus Partner of Hoxton Ventures.

About Phagos

Phagos is a pioneering biotech company dedicated to ending bacterial diseases. Using AI-driven bacteriophage therapies, it develops ultra-precise, personalised treatments for animals, targeting infections like Salmonella and E. coli, with long-term plans to extend solutions to human health, tackling antibiotic resistance and advancing global health innovation.